Abstracts

Statins Improve SVR, Reduce Fibrosis Progression and HCC Among HCV+ Persons

Background: Statins have been variably noted to affect HCV treatment response, fibrosis progression, and hepatocellular carcinoma (HCC) incidence. However, this has not been evaluated in a large national cohort while controlling for important confounders. Methods: Within Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES), we identified those Veterans initiated on HCV treatment with a follow…

Real-World Data on HIV-Positive Patients With HCV Treated With Sofosbuvir and/or Simeprevir

Background: We are investigating the effectiveness of simeprevir (SMV) and sofosbuvir (SOF) in a real-world setting for patients with HIV/HCV co-infection. Methods: Data on 80 HIV/HCV co-infected patients who initiated therapy between 12/2013 and 8/2014 were analyzed. Baseline and week-2 on-treatment data are reported. Week-4 and Week-12 post end-of-treatment responses were examined to determine the…

Sofosbuvir/Daclatasvir in HIV/HCV Co-infected Patients With Extensive Liver Fibrosis

Background: All-oral combination of sofosbuvir (SOF), a pan genotypic HCV NS5B inhibitor, plus daclatasvir (DCV), NS5A inhibitor, has been poorly evaluated in HIV/HCV co-infected. Interactions between this anti-HCV regimen and antiretroviral drugs (ART) have been poorly investigated. We evaluated the safety and efficacy of SOF plus DCV and plasmatic concentrations of antiviral drugs in HCV/HIV…

Simeprevir/Sofosbuvir vs Triple Therapy (Telaprevir or Boceprevir) for HCV GT1: A cost analysis

Background: Simeprevir plus sofosbuvir (with or without ribavirin) (SMV/SOF) increases rates of sustained virologic response (SVR) over telaprevir- or boceprevir-based triple therapy (TT) (89-100% vs 64- 75%). Our objective was to examine the total treatment cost and cost per SVR of SMV/SOF versus TT. Methods: Patients were included if they had chronic hepatitis C, were…

Five–Year Risk of Late Relapse or Reinfection With Hepatitis C After Sustained Virological Response: Meta-analysis of 49 Studies in 8534 Patients

Background: Combination treatment with direct acting antivirals can lead to sustained virological response (SVR) in over 90% of people with Hepatitis C (HCV) infection. However, subsequent recurrence of HCV (either from late relapse or re-infection) reverses the beneficial effects of SVR. This analysis aimed to estimate the 5-year risk of HCV late relapse or re-infection…

Impact of SVR on Liver Decompensation and Hepatic Fibrosis Markers in HIV/HCV

Background: It remains unclear if rates of hepatic decompensation (HD) and changes in liver fibrosis differ between HIV/hepatitis C virus (HCV)-coinfected and HCV-monoinfected patients after sustained virologic response (SVR) to HCV therapy. We evaluated the risk of HD and changes in liver fibrosis after SVR in HCV-treated coinfected and monoinfected patients. Methods: We performed a…